Neutral
Our verdict — Morgan Stanley ranks #49 of 64 in our leaderboard: 61.3% hit rate across all stocks, 12.2% average gain per call, +3 pts vs its sector.
Neurocrine Biosciences (NBIX) price target — analyst by analyst
Neurocrine Biosciences · Health Care · ref. ETF XLV · price $155.92
By Rédaction JPI Invest · updated
In short — 18 price targets published on Neurocrine Biosciences over 90 days: 15 bullish, 0 bearish (83% positive), median target $204. The highest-ranked firm to weigh in is Canaccord Genuity (rank 10, 64.7% hit rate). For each call below we show the firm's real track record — not just its opinion.
The last 18 analyst calls on NBIX
Newest first. The "verdict" is our read on the firm, based on its past calls replayed against actual prices.
Bullish
Our verdict — Canaccord Genuity ranks #10 of 64 in our leaderboard: 64.7% hit rate across all stocks, 28.8% average gain per call, +12 pts vs its sector.
Bullish
Our verdict — Truist Securities ranks #51 of 64 in our leaderboard: 63.6% hit rate across all stocks, 14.6% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — Wedbush ranks #12 of 64 in our leaderboard: 72% hit rate across all stocks, 31.5% average gain per call, +11 pts vs its sector.
Bullish
Our verdict — Citigroup ranks #24 of 64 in our leaderboard: 65.5% hit rate across all stocks, 20.1% average gain per call, +5 pts vs its sector.
Bullish
Our verdict — RBC Capital ranks #62 of 64 in our leaderboard: 61.2% hit rate across all stocks, 9% average gain per call, -2 pts vs its sector.
Neutral
Our verdict — Morgan Stanley ranks #49 of 64 in our leaderboard: 61.3% hit rate across all stocks, 12.2% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — TD Cowen ranks #60 of 64 in our leaderboard: 61.3% hit rate across all stocks, 14% average gain per call, 0 pts vs its sector.
Bullish
Our verdict — Piper Sandler ranks #26 of 64 in our leaderboard: 62.1% hit rate across all stocks, 19.9% average gain per call, +5 pts vs its sector.
Bullish
Our verdict — Cantor Fitzgerald ranks #11 of 64 in our leaderboard: 57.8% hit rate across all stocks, 37.1% average gain per call, +12 pts vs its sector.
Bullish
Our verdict — Guggenheim ranks #40 of 64 in our leaderboard: 65.7% hit rate across all stocks, 14.3% average gain per call, +4 pts vs its sector.
Bullish
Our verdict — Stifel ranks #20 of 64 in our leaderboard: 63% hit rate across all stocks, 21.6% average gain per call, +6 pts vs its sector.
Bullish
Our verdict — Needham ranks #14 of 64 in our leaderboard: 65.1% hit rate across all stocks, 33.4% average gain per call, +10 pts vs its sector.
Bullish
Our verdict — Guggenheim ranks #40 of 64 in our leaderboard: 65.7% hit rate across all stocks, 14.3% average gain per call, +4 pts vs its sector.
Bullish
Our verdict — Wells Fargo ranks #47 of 64 in our leaderboard: 61.8% hit rate across all stocks, 14.5% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — Truist Securities ranks #51 of 64 in our leaderboard: 63.6% hit rate across all stocks, 14.6% average gain per call, +3 pts vs its sector.
Neutral
Our verdict — BMO Capital ranks #43 of 64 in our leaderboard: 65.4% hit rate across all stocks, 15.1% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — RBC Capital ranks #62 of 64 in our leaderboard: 61.2% hit rate across all stocks, 9% average gain per call, -2 pts vs its sector.
⚠️ Price targets as published by the firms, timestamped at their publication date. The upside shown is vs the price on the day of the call, not today's price. Informational data, not investment advice.
Frequently asked questions
What are analysts saying about NBIX right now?
Over the last 90 days, 18 price targets were published on Neurocrine Biosciences: 15 bullish and 0 bearish (83% positive). The median target is $204. The latest call is from August 13, 2026.
Should you trust these price targets?
Not blindly — that's the point of this page: next to each call we show the firm's real track record — its rank among 64 tracked firms, its hit rate and its average gain per call. An ambitious target from a firm that is wrong 6 times out of 10 is not worth the same as one from a consistent firm.
Which firm covering NBIX is the most reliable?
Among the firms that published on Neurocrine Biosciences in the last 90 days, our highest-ranked is Canaccord Genuity (rank 10 of 64, 64.7% hit rate, 28.8% average gain per call).
Where does this data come from?
From analyst price targets, timestamped at publication then replayed against the actual price. Firm rankings come from our analyst leaderboard. Updated daily.
💬 A question about Neurocrine Biosciences? The JPI assistant answers using our backtest data.
Keep exploring Neurocrine Biosciences